Literature DB >> 21533825

Gender effect on time to levodopa-induced dyskinesias.

Sharon Hassin-Baer1, Irena Molchadski, Oren S Cohen, Zeev Nitzan, Lilach Efrati, Olga Tunkel, Evgenia Kozlova, Amos D Korczyn.   

Abstract

Levodopa-induced dyskinesias (LID) are commonly observed during long-term treatment of patients with Parkinson's disease (PD). The impact of non-pharmacological factors on the latency to LID appearance is not known. The aim of the paper was to identify factors associated with time to appearance of LID. Consecutive PD patients treated with levodopa (n = 155) were included in this historical prospective analysis and LID and non-LID groups were compared. The relationship between possible risk factors and the time of LID onset was explored using the Kaplan-Meier method and the Cox multivariate regression model, controlling for the confounding effects of gender, age of disease onset, time to initiation of levodopa treatment, and history of smoking. Patients with LID (57.4%) were significantly younger at disease onset and had a slightly longer latency from diagnosis to levodopa treatment than those without; disease duration and age had no effect on LID appearance. Female gender was associated with a shorter time to LID and the median time to LID was 6 years for males and 4 years for females (p = 0.004). In the multivariate survival analysis a younger age of onset of PD and a longer time from diagnosis to levodopa treatment initiation were also associated with a shorter time to LID appearance (p = 0.030 and 0.036, respectively). Female gender is associated with a significantly shorter latency to LID appearance. Younger age at PD diagnosis and a longer time until starting levodopa are associated with both higher likelihood to develop LID, and a shorter latency until LID were observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533825     DOI: 10.1007/s00415-011-6067-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

2.  Risk factors for levodopa-induced dyskinesias in Parkinson's disease.

Authors:  F Grandas; M L Galiano; C Tabernero
Journal:  J Neurol       Date:  1999-12       Impact factor: 4.849

3.  Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Judith A Strong; Arif Dalvi; Fredy J Revilla; Alok Sahay; Frederick J Samaha; Jeffrey A Welge; Jianhua Gong; Maureen Gartner; Xia Yue; Lei Yu
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

4.  The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease.

Authors:  Boris Kandinov; Nir Giladi; Amos D Korczyn
Journal:  Parkinsonism Relat Disord       Date:  2007-02-01       Impact factor: 4.891

5.  Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.

Authors:  Robert A Hauser; Michael P McDermott; Susan Messing
Journal:  Arch Neurol       Date:  2006-12

6.  Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).

Authors:  Jagdish C Sharma; Lorna Macnamara; Mohammad Hasoon; Michael Vassallo; Ian Ross
Journal:  Parkinsonism Relat Disord       Date:  2006-08-28       Impact factor: 4.891

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.

Authors:  M Watanabe; S Harada; T Nakamura; N Ohkoshi; K Yoshizawa; A Hayashi; S Shoji
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

9.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

10.  L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.

Authors:  R Kaiser; A Hofer; A Grapengiesser; T Gasser; A Kupsch; I Roots; J Brockmöller
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

View more
  17 in total

1.  Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Natalie Kaplan; Aya Vituri; Amos D Korczyn; Oren S Cohen; Rivka Inzelberg; Gilad Yahalom; Evgenia Kozlova; Roni Milgrom; Yael Laitman; Eitan Friedman; Saharon Rosset; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-03-15       Impact factor: 3.444

Review 2.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

3.  Sex disparities in health and health care utilization after Parkinson diagnosis: Rethinking PD associated disability.

Authors:  Michelle E Fullard; Dylan P Thibault; Veronica Todaro; Susan Foster; Lori Katz; Robin Morgan; Drew S Kern; Jason M Schwalb; Enrique Urrea Mendoza; Nabila Dahodwala; Lisa Shulman; Allison W Willis
Journal:  Parkinsonism Relat Disord       Date:  2017-12-14       Impact factor: 4.891

4.  The impact of early versus late levodopa administration.

Authors:  Gilad Yahalom; Oren S Cohen; Naama Warmann-Alaluf; Chen Shabat; Hanna Strauss; Sandra Elincx-Benizri; Simon Israeli-Korn; Esther Stein; Lior Greenbaum; Sharon Hassin-Baer
Journal:  J Neural Transm (Vienna)       Date:  2016-12-21       Impact factor: 3.575

Review 5.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

Authors:  Tai N Tran; Trang N N Vo; Karen Frei; Daniel D Truong
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

Review 6.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

7.  Quantitative motor assessment of dyskinesias in Parkinson's disease.

Authors:  Eva Schaeffer; Walter Maetzler; Inga Liepelt-Scarfone; Christian Sass; Ralf Reilmann; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2015-02-25       Impact factor: 3.575

8.  BDNF rs6265 single-nucleotide polymorphism is involved in levodopa-induced dyskinesia in Parkinson's disease via its regulation of the cortical thickness of the left postcentral gyrus.

Authors:  Hui-Min Sun; Li-Na Wang; Min Ji; Cai-Ting Gan; Yong-Sheng Yuan; Xing-Yue Cao; Heng Zhang; Ke-Zhong Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-06

9.  Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS.

Authors:  Carmen Rodriguez-Blazquez; Anette Schrag; Alexandra Rizos; K Ray Chaudhuri; Pablo Martinez-Martin; Daniel Weintraub
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

10.  Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.

Authors:  Lior Greenbaum; Stefano Goldwurm; Polina Zozulinsky; Tzuri Lifschytz; Oren S Cohen; Gilad Yahalom; Roberto Cilia; Silvana Tesei; Rosanna Asselta; Rivka Inzelberg; Yoav Kohn; Sharon Hassin-Baer; Bernard Lerer
Journal:  J Mol Neurosci       Date:  2013-05-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.